|Bid||105.85 x 1000|
|Ask||105.97 x 900|
|Day's Range||104.02 - 108.14|
|52 Week Range||84.45 - 202.45|
|Beta (3Y Monthly)||1.57|
|PE Ratio (TTM)||3.47|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ligand Pharmaceuticals Incorporated (LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases. Ms. Boyce's appointment increases the number of Ligand directors to nine.
VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.
Short position in Ligand pharmaceuticals, long position in Geospace Technologies, contribute to 70.27 percent net return in 1H, 2019 SHELBURNE, Vt ., July 16, 2019 /PRNewswire/ -- Lemelson Capital Management, ...
SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure. The smaller delivery volume enables use of established drug container and device technology developed for insulin and other biologics, resulting in faster development and reduced cost. SQ Innovation to use advanced 3 mL drug delivery platform by Sensile Medical AG, a Gerresheimer company, for the novel treatment.
Ligand Pharmaceuticals Incorporated (LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target. PhoreMost has identified and validated the target using its next-generation SITESEEKER® phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.
Ligand Pharmaceuticals Incorporated (LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in the mid-to-high single digit range, depending on revenue. In addition, Ligand is eligible to receive an additional fee, payable in cash or Cumulus equity, upon Cumulus achieving specified financing-related events.
Ligand Pharmaceuticals Incorporated (LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones. Novan is responsible for all expenses to develop or commercialize SB206, and will use 100% of the proceeds from this transaction in the development and pursuit of regulatory approval for SB206.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (LGND). This transaction further enables the accelerated advancement of the molluscum Phase 3 program within the overall Novan mid-to-late stage clinical development portfolio. Under the terms of this development funding and royalty agreement, Ligand will provide funding of $12 million in exchange for a tiered royalty of 7 to 10% which will be based on future North American sales of SB206 for the molluscum indication.
Ligand Pharmaceuticals Incorporated (LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand also provides below a summary of the findings of a survey of clinicians on radiocontrast agent selection and use.
Ligand Pharmaceuticals Incorporated announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Ligand Pharmaceuticals Incorporated (LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of Sage Therapeutics’ (SAGE) ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth. PPD can affect women during pregnancy or after childbirth.
Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conferences:
At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (LGND) reviewed the recent progress of its business and financial growth outlook. Management provided additional details on its 2019 financial guidance and a preliminary financial outlook for 2020, discussed its technology platforms, including the opportunity and importance of its OmniAb technology platform. Ligand leverages its diversification with Shots on Goal, which are programs fully-funded by partners and backed by Ligand’s patents, know-how and/or data.
COLUMBUS, Ohio, March 11, 2019 -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific.
Ligand Pharmaceuticals Incorporated (LGND) and Royalty Pharma announce the sale of Ligand’s Promacta®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827 million in cash. Promacta (eltrombopag) is known as Revolade® outside the U.S. and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019.